Celgene reports positive data from combination lymphoma therapy trial

Celgene has announced the findings of a phase IIIb clinical trial that demonstrates the benefits offered by a new lymphoma treatment regimen.

The MAGNIFY study assessed the performance of a new combination of Revlimid plus rituximab –  a regimen known as R2 – in patients with relapsed or refractory marginal zone lymphoma.

An interim data analysis showed that patients with early relapse and double-refractory disease generally experienced strong levels of clinical activity with R2 across indolent non-Hodgkin lymphomas, marginal zone and follicular histologies.

Responses were also seen in poor-risk patient subpopulations, including early relapsing patients and patients who were refractory to multiple lines of therapy.

The company is also awaiting the responses of the phase III AUGMENT and RELEVANCE studies to support future regulatory applications for this treatment approach.

Michael Pehl, president for haematology and oncology at Celgene, said: "We hope that the growing volume of evidence for R2 may lead to new options for patients that offer an alternative to traditional cytotoxic chemotherapies."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.